Selected from thousands of international nominations, this award recognises CV6 Therapeutics’ innovative approach to cancer treatment and highlights the strength of Northern Ireland’s growing life sciences sector.
CV6-168 is a first-in-class oral medicine designed to enhance the effectiveness of 5-fluorouracil (5-FU), a widely used chemotherapy drug in the treatment of several major cancers. Developed using the company’s innovative Genomic Uracil Stress Response (GUSR) platform, the treatment aims to improve the effectiveness of established cancer therapies while minimising additional burden on patients.
The medicine is currently undergoing a Phase 1a clinical trial, with dose escalation continuing and no dose-limiting toxicities observed to date. The programme has also received clearance to progress into Phase 1b development.
Read the original announcement: CV6 Therapeutics Newsroom
Find out more about CV6 Therapeutics: Visit their website
The British Business Bank has announced
the Investment Fund for Northern Ireland has surpassed £100 million in total investment, marking 75 investments into 64 businesses since launching in November 2023. The fund has deployed more than £44 million to date, helping unlock in excess of £62 million in private sector investment alongside it.
Armagh-based, female-founded tech start-up, Needi, has raised just under £900,000 in a new funding round. Pictured are Needi’s co-founder Louise Doyle (right), with British Business Bank senior investment manager Sue Barnard (left) and Claudine Owens from Clarendon Fund Managers.